Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

544230, A61K 31495, C07D47106

Patent

active

055654533

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

The present invention is directed to certain 2- substituted perhydro-1H-pyrido[1,2-a]pyrazines which are depicted by the formula (I) as defined below, and to pharmaceutical compositions comprising these compounds, and a method of treating psychotic diseases therewith.
Commonly-owned U.S. patent application No. 07/661,791, filed Feb. 27, 1991 U.S. Pat. No. 5,157,034, the disclosure of which is herein incorporated by reference, is directed to both racemic and optically active perhydro-1H-pyrido[1,2-a]pyrazines having the formula ##STR2## wherein Z is H or Cl; ##STR3## where Y.sup.1 is CH.sub.2, S, O or NH; Y.sup.2 and Y.sup.3 are taken separately and Y.sup.2 and Y.sup.3 are each independently hydrogen or methyl, or Y.sup.2 and Y.sup.3 are taken together and are (CH.sub.2).sub.q ; p is 1 or 2, q is 2, 3, 4 or 5; and r is 0 or 1.
U.S. Pat. No. 4,956,368, issued Sep. 11, 1990 discloses various metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro(4,5)deca ne-7,9-dione which are particularly useful in the treatment of psychotic disorders, especially derivatives thereof which have been oxygenated at specified sites about the original structure, rearranged compounds, and prodrug formulations of these species. One particularly desired group of compounds have the general formula ##STR4## where: R.sup.1 is hydrogen, hydroxyl, alkoxy, acyloxy and oxo;
Perhydro-1H-pyrido[1,2-a]-pyrazines of the formula ##STR5## wherein X.sup.a is N or CH and L.sup.a represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals have been reported to possess useful anxiolytic activity, Bright and Desai, International Application published under the PCT as publication No. WO 90/08144.
A variety of compounds are reported to be in possession of neuroleptic activity useful in the treatment of psychotic diseases. These include piperidine derivatives of the formula ##STR6## wherein t is 1 or 2, Ar is naphthyl or one of a variety of bicyclic heteroaryl groups, including benzisothiazoyl, and X.sup.b and Y.sup.b together with the attached phenyl group form a similar such bicyclic heteroaryl group (Lowe, III et al., U.S. Pat. No. 4,831,031); and compounds of the formula ##STR7## wherein Q represents certain bicyclic heteroaryl groups, Alk is alkanediyl X.sup.c represents, O, S, NH, or substituted NH (Kennis et al., U.S. Pat. No. 4,957,916).


SUMMARY OF THE INVENTION

The present invention is directed to 2-substituted perhydro-1H-pyrido-[1,2-a]pyrazines having the formula ##STR8## wherein R is H or R.sup.1 C(.dbd.O), wherein R.sup.1 is (C.sub.1 -C.sub.6)alkyl, phenyl or substituted phenyl.


DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to 2a-oxo-substituted perhydro-1H-pyrido[1,2-a]pyrazines having the formula I wherein the stereochemistry at the 2a position is R or S; or a diastereomeric mixture which comprises the compound of formula (I) having 2aR, 7S, 9aS stereochemistry in combination with the compound of formula (I) having 2aS, 7S, 9aS stereochemistry; and a pharmaceutically acceptable acid addition salt thereof; and wherein R is hydrogen or R.sup.1 C(.dbd.O) wherein R.sup.1 is (C.sub.1 -C.sub.6)-alkyl, phenyl or substituted phenyl.
As used in this invention "alkyl" means straight or branched carbon chains of up to six carbon atoms.
"Substituted phenyl" means a phenyl ring having one or two substitutions selected from (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkoxy, halo, nitro and trifluoromethyl.
In another aspect, this invention is directed toward a pharmaceutical composition for the treatment of psychotic disorders which comprises a neuroleptic effective amount of a compound of formula I and a pharmaceutically acceptable carrier.
In yet another aspect, this invention is directed toward a method of treating psychotic disorders which comprises administering to a psychotic patient in need of such treatment a neuroleptic effective amount of a compound of formula I.
A preferred compound of this invention is repre

REFERENCES:
patent: 4831031 (1989-05-01), Lowe, III et al.
patent: 4956368 (1990-09-01), Cipollina et al.
patent: 4957916 (1990-09-01), Kinnis et al.
"Biochemical Profile of Risperidone, A New Antipsychotic", Leysen, J. E., et al., J. Pharm. Exp. Ther., 247, 661-670 at 662, 1988.
"The Oxford Textbook of Clinical Pharmacology and Drug Therapy", pp. 23-24, Grahame-Smith, D. G., et al. 1984.
Goodman and Gilman, "The Pharmacological Basis of Therapeutics", p. 13, 1990.
"Pharmacology of Risperidone (R 64 766), a New Antipsychotic with Serotonin-S.sub.2 and Dopamine-D.sub.2 Antagonistic Properties", Janssen, P. A. J., et al., Pharm. Exp. Ther., 244(2):685 1988.
"Risperidone in the Treatment of Acute Exacerbation of Chronic Schizophrenia", Borison, R. L. et al., Schizophrenia Research, 4(3):314-315, 1991.
"Therapeutic Effect and Safety of Increasing Doses of Risperidone (R 64766) in Psychotic Patients", Mesotten, et al., Psychopharmacology, 99:445-449, 1989.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1246323

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.